ARDMQ Aradigm

Aradigm Corporation (the “Company,” “our company,” “we,” “our,” or “us”) are an emerging specialty pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Over the last decade, we invested a large amount of capital to develop drug delivery technologies, particularly the development of a significant amount of expertise in respiratory (pulmonary) drug delivery as incorporated in our lead product candidate that recently completed two Phase 3 clinical trials, Linhaliq inhaled ciprofloxacin, formerly known as Pulmaquin® . The key asset we have focused our efforts on in recent years is our inhaled ciprofloxacin formulations. We believe that our cash and cash equivalents of approximately $7.1 million as of December 31, 2017, will only be sufficient to fund our operations for the first quarter of 2018. We will not be able to maintain our current level of regulatory and product development activity and there is substantial doubt about our company’s ability to continue as a going concern unless we raise additional capital in early 2018. Accordingly, we need to raise additional capital through the issuance of debt or equity securities, royalty financing transactions, strategic transactions or otherwise to enable us to maintain our business operations and to continue development of our lead product candidate Linhaliq and other products, and if we are unable to do so we will need to dispose of our assets or technology or cease operations. The discussion of future prospects of our business below is based on the assumption that we are able to obtain the necessary capital to continue to operate our business as described below.

Company profile

Fiscal year end
IRS number

ARDMQ stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


15 Nov 18
29 Jul 21
31 Dec 21

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 1 2 -50.0%
Opened positions 0 0
Closed positions 1 0 NEW
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 2 EXIT
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
Focused Wealth Management 0 -2 EXIT
Proequities 0 0

Financial report summary

Content analysis
H.S. junior Avg
New words: alleged, Apulmiq, Arikayce, attributable, CFU, description, exacerbation, hearing, immaterial, narrative, nonrecurring, Panel, range, weighed
Removed: appointment, area, Black, body, Canadian, combined, contrast, DRDC, emphysema, encouraging, essential, free, higher, intracellular, mallei, mycobacterial, NIH, ofMycobacterium, people, percent, pointing, prolonged, rapidly, released, route, show, showed, statistically, supplement, targeted, unencapsulated, uptake